Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan-hyaluronic acid complex - Monash University/Alchemia

Drug Profile

Irinotecan-hyaluronic acid complex - Monash University/Alchemia

Alternative Names: HA-irinotecan; Hyaluronan irinotecan complex; Hyaluronic acid irinotecan complex; HyCAMP; Irinotecan hyaluronan complex

Latest Information Update: 01 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monash University
  • Developer Alchemia
  • Class Alkaloids; Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Suspended Colorectal cancer

Most Recent Events

  • 01 Aug 2019 Phase II development is ongoing in Australia (ACTRN12611000520932)
  • 01 May 2015 Irinotecan-hyaluronic acid complex is still in phase II development for Small cell lung cancer in Australia
  • 01 May 2015 Alchemia suspends a phase II trial in Colorectal cancer in Australia (NCT02216487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top